Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 853 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Control Clear all
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 3, 2026, 4:22 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348
View directory record Official record
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions
Halneuron, Placebo, Halneuron (Open Label Extension)
Drug
Lead sponsor
Dogwood Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy

NCT02167217
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisolone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 30 Months · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Sacramento, California • Orlando, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 3, 2026, 4:22 AM EDT
Active, not recruiting Not applicable Interventional

Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy

NCT05777317
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
10 kHz SCS, CMM alone
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

NCT04281485
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06939926, Placebo
Genetic · Other
Lead sponsor
Pfizer
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2039
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 3, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ALXN1720, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)

NCT00001550
View directory record Official record
Conditions
Muscle Rigidity, Spasm, Stiff Man Syndrome
Interventions
IVIg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 3, 2026, 4:22 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating Avive+ Soft Tissue Matrix for Prevention of Superficial Radial Nerve Morbidity Following Radial Forearm Free Flap Harvest

NCT07558096
View directory record Official record
Conditions
Head and Neck Cancer (H&N)
Interventions
Standard Closure (Control), Avive+ Intervention
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 3, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

NCT05349721
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PTC857, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Orange, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

NCT03579693
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia, Frailty
Interventions
CoQ10, Nicotinamide riboside, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

NCT03052751
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
UCB7665, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Levetiracetam for Treatment of Pain Associated With Fibromyalgia

NCT00254657
View directory record Official record
Conditions
Fibromyalgia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial

NCT00437411
View directory record Official record
Conditions
Fibromyalgia
Interventions
Affective Self-Awareness workshop
Behavioral
Lead sponsor
Mike Hsu
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 3, 2026, 4:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020
View directory record Official record
Conditions
Dermatomyositis
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 3, 2026, 4:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Cannabis for Spasticity in Multiple Sclerosis

NCT00260741
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Smoked Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

NCT02297412
View directory record Official record
Conditions
Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions
Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 3, 2026, 4:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Telemedicine Clinical Trial for Cognitive Behavioral Therapy in Familial Dysautonomia

NCT03911063
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
CBT sessions, Talking Sessions
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT03861481
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 3, 2026, 4:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 3, 2026, 4:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 3, 2026, 4:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

NCT05361811
View directory record Official record
Conditions
Neurofibromatosis 1, Noonan Syndrome, Legius Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome
Interventions
Waitlist, ACT Intervention
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 4:22 AM EDT